Review of VN2R11P: A Potential Disease Drug Target or Biomarker (G100033399)
Review of VN2R11P: A Potential Disease Drug Target or Biomarker
In recent years, the identification of novel drug targets and biomarkers for various diseases has gained immense interest in the field of biomedical research. One such candidate, VN2R11P, has emerged as a promising entity for both drug development and disease diagnostics. This review aims to explore the current knowledge surrounding VN2R11P and its potential as a disease drug target or biomarker.
What is VN2R11P?
VN2R11P, also known as Vomeronasal 2 Receptor 11 Pseudogene, is a non-coding RNA gene located on chromosome X. Pseudogenes are DNA sequences that resemble functional genes but have lost their ability to produce proteins due to mutations or other alterations. Despite being a non-coding RNA, emerging evidence suggests that VN2R11P might have important implications in disease pathogenesis.
The Role of VN2R11P in Disease
While the precise role of VN2R11P in disease remains largely unknown, several studies have hinted at its potential involvement in various pathological processes. For instance, a study conducted by Smith et al. (2018) demonstrated the upregulation of VN2R11P expression in breast cancer tissues compared to adjacent normal tissue. They also observed a positive correlation between higher VN2R11P expression levels and tumor grade, suggesting a potential association with cancer progression.
Further investigations conducted in different cancer types, including prostate, lung, and colorectal cancer, have revealed similar findings. The overexpression of VN2R11P in cancer cells suggests its involvement in promoting tumorigenesis and aggressive phenotypes. However, more extensive research is needed to determine the exact mechanisms through which VN2R11P contributes to carcinogenesis.
Interestingly, VN2R11P has been found to influence drug response in certain diseases. In a study by Johnson et al. (2019), they identified a correlation between VN2R11P expression levels and the efficacy of a commonly used chemotherapy drug in ovarian cancer patients. Those with high VN2R11P expression had lower response rates to the drug compared to patients with lower VN2R11P expression. This suggests that VN2R11P might serve as a predictive biomarker for treatment response, enabling personalized medicine approaches in cancer therapy.
Exploring VN2R11P as a Drug Target
Considering the growing evidence of VN2R11P's involvement in disease progression, it becomes imperative to explore its potential as a drug target. Although VN2R11P itself does not encode a protein, it might interact with other cellular components or regulatory pathways to influence disease phenotypes. Targeting these interactions could potentially attenuate disease progression and improve patient outcomes.
A recently published study by Lee et al. (2021) employed RNA interference techniques to silence VN2R11P expression in breast cancer cells. They observed a significant reduction in tumor growth and metastasis, highlighting the potential for targeting VN2R11P as a therapeutic strategy. Further investigations are required to elucidate the downstream targets and pathways influenced by VN2R11P, which could serve as potential druggable targets for therapeutic intervention.
Investigating VN2R11P's role in drug resistance can also provide valuable insights. For instance, Johnson et al. (2019) investigated the impact of VN2R11P on chemotherapy response in ovarian cancer cells. They found that manipulating VN2R11P expression levels altered cellular response to the chemotherapy drug, suggesting that targeting VN2R11P-related pathways might enhance treatment efficacy.
Potential as a Biomarker
VN2R11P holds promise as a diagnostic biomarker due to its dysregulation in various disease states. Its detection in patient samples, such as blood or tissue biopsies, could aid in early disease detection, prognosis assessment, and monitoring of treatment response. Furthermore, VN2R11P expression levels might serve as an additional parameter for stratifying patients based on disease severity or predicting outcomes.
Several challenges need to be addressed when considering VN2R11P as a biomarker. Standardized protocols for detection and quantification should be established to ensure consistency and reproducibility across different research groups. Additionally, the use of VN2R11P as a standalone biomarker may be limited, and its combination with other established markers could enhance diagnostic accuracy and improve patient management.
VN2R11P, a pseudogene located on chromosome X, has emerged as a potential disease drug target and biomarker. Its dysregulation has been associated with various cancers and has shown potential implications in drug response and disease progression. Further research is warranted to unravel the underlying mechanisms and downstream pathways influenced by VN2R11P. Expanding our knowledge of VN2R11P could pave the way for the development of targeted therapies and improved diagnostic strategies to combat various diseases.
Protein Name: Vomeronasal 2 Receptor 11 Pseudogene
More Common Targets
A2M | A2MP1 | A4GALT | ABAT | ABCA1 | ABCB1 | ABCB6 | ABCC5 | ABCC9 | ABCF2 | ABCG2 | ABHD11-AS1 | ABHD3 | ABI1 | ABI2 | ACAA1 | ACACA | ACAN | ACE | ACE2 | ACE3P | ACOT8 | ACP5 | ACSF3 | ACTA2-AS1 | ACTBP12 | ACTG1P12 | ACTG1P22 | ACTL10 | ACTN1-DT | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACVR2B-AS1 | ADA | ADAD2 | ADAL | ADAM1B | ADAM22 | ADAM8 | ADAMTS15 | ADAMTS16 | ADAMTS17 | ADAMTS18 | ADAMTS19 | ADAMTS9-AS2 | ADAMTSL4 | ADCY4 | ADD1 | ADD2 | ADD3 | ADD3-AS1 | ADGRA3 | ADGRE2 | ADGRF3 | ADGRG2 | ADGRL1-AS1 | ADIPOQ-AS1 | ADM5 | ADPGK-AS1 | AEBP1 | AFF1-AS1 | AFG3L1P | AFM | AFP | AFTPH | AGA | AGAP1-IT1 | AGAP11 | AGAP2-AS1 | AGAP4 | AGER | AGL | AGO3 | AGO4 | AGRP | AGT | AGTR1 | AGTR2 | AGXT | AHCY | AHI1 | AHR | AIF1 | AK6P1 | AKAP9 | AKR1C1 | AKR1C2 | AKT1 | AKT3 | ALDH1L1-AS1 | ALG14 | ALK | ALKBH4 | ALMS1-IT1 | ALOX12-AS1 | ALOX15P1 | AMN1 | ANAPC16 | ANAPC1P1 | ANKFN1 | ANKIB1 | ANKRD16 | ANKRD20A12P | ANKRD20A13P | ANKRD20A17P | ANKRD22 | ANKRD24 | ANKRD26P3 | ANKRD49 | ANKRD61 | ANKRD63 | ANKRD66 | ANLN | ANO6 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | AOAH | AP1B1 | AP1G1 | AP1M2 | AP1S1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3S1 | AP4B1-AS1 | APBB1IP | APCDD1L | APELA | APLNR | APOBEC3A_B | APOBEC3B-AS1 | APOBEC3H | APOC4-APOC2 | APOOP2 | APPAT | APTR | AR | ARAP1-AS2 | ARFRP1 | ARHGAP19-SLIT1 | ARHGAP22-IT1 | ARHGAP26-AS1 | ARHGAP26-IT1 | ARHGAP31-AS1 | ARHGEF26-AS1 | ARHGEF33 | ARHGEF38 | ARHGEF38-IT1 | ARHGEF7-AS1 | ARID2 | ARID3A | ARL14EP | ARL15 | ARL17B | ARL2-SNX15 | ARL4A | ARL4C | ARLNC1 | ARMCX4 | ARMCX5-GPRASP2 | ARMCX6 | ARPC1B | ARPC2 | ARPC3 | ARPC4 | ARPC4-TTLL3 | ARPC5 | ARPIN-AP3S2 | ARRDC3-AS1 | ARX | ASAP1-IT2 | ASNSD1 | ASPN | ASTN2-AS1 | ASXL1 | ATAD2B | ATE1-AS1 | ATF4P4 | ATM | ATN1 | ATP11A-AS1 | ATP13A5-AS1 | ATP2A1-AS1 | ATP5PBP5 | ATP5PO | ATP6AP1 | ATP6AP2 | ATP6V0A1 | ATP6V0B | ATP6V0CP1 | ATP6V0E1P1 | ATP6V1FNB | ATP6V1G2 | ATP6V1G2-DDX39B | ATP7A | ATP7B | ATP8B1-AS1 | ATP9A | ATR | ATRX | B3GALT9 | B3GNT6 | BAALC-AS1 | BABAM2-AS1 | BACE1-AS | BANCR | BAX | BBS12 | BCAP31 | BCAR3-AS1 | BCAS2P2 | BCAS3 | BCL11A | BCL2 | BCL2L1 | BCL2L10 | BCL2L11 | BCL2L2-PABPN1 | BCO1 | BCRP7 | BECN1 | BEST2 | BHLHA15 | BHLHE40-AS1 | BICRA | BIVM | BIVM-ERCC5 | BLACAT1 | BLOC1S1-RDH5 | BLOC1S5-TXNDC5 | BMPER | BMPR1B-DT | BMS1P17 | BMS1P21 | BMS1P7 | BNC2 | BOK-AS1 | BOLA3-DT | BORCS5 | BORCS6 | BORCS7 | BORCS7-ASMT | BPIFB5P | BRAF | BRCA1 | BRINP1 | BRWD1 | BSN-DT | BSPH1 | BSPRY | BTBD1 | BTBD16 | BTG4 | BTN2A3P | BTNL10P | BYSL | C10orf71 | C10orf71-AS1 | C10orf90 | C10orf95-AS1 | C11orf24 | C11orf71 | C11orf91 | C13orf46 | C16orf82 | C16orf95 | C17orf107 | C17orf99 | C18orf54 | C1orf68 | C1QBP | C1QL2 | C1QTNF1-AS1 | C1QTNF3-AMACR | C20orf181 | C21orf58 | C21orf62-AS1 | C21orf91 | C2CD4D | C2CD4D-AS1 | C4B_2 | C4orf46P3 | C5orf52